Enhancing Care in Cardiogenic Shock: Role of Palliative Care in Acute Cardiogenic Shock Through Destination Therapy

Annie Hung1, Michael Slawnych2, Caroline McGuinty3

  • 1Division of Cardiology, Queen's University, Kingston, Ontario, Canada.

PubMed

Insights

Early integration of palliative care (PC) can improve quality of life for patients with cardiogenic shock (CS). This review highlights strategies for incorporating PC alongside advanced therapies like mechanical circulatory support (MCS) and extracorporeal membrane oxygenation (ECMO).

Area of Science:

  • Cardiology
  • Palliative Care
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) has high mortality despite advances in management.
  • Palliative care (PC) improves quality of life for patients with life-threatening illnesses.
  • Current PC utilization in CS is low, despite benefits observed in heart failure and critical care.

Purpose of the Study:

  • To review the role of PC throughout the CS care continuum.
  • To explore challenges in integrating PC with advanced therapies like MCS and ECMO.
  • To advocate for early PC integration in CS management.

Main Methods:

  • Literature review focusing on PC in cardiogenic shock.
  • Analysis of PC integration with mechanical circulatory support (MCS) and extracorporeal membrane oxygenation (ECMO).
  • Discussion of strategies for acute and chronic CS care.

Main Results:

  • PC use in CS is currently low.
  • Advanced therapies (MCS, ECMO) present unique challenges for goals-of-care discussions.
  • Evidence suggests PC can reduce symptom burden and healthcare utilization.

Conclusions:

  • PC should be integrated early in the management of CS.
  • PC should complement, not replace, aggressive life-sustaining measures.
  • Challenging the traditional view of PC as solely an end-of-life intervention is crucial.

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
740
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
167
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
505
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K